Accessibility Menu
HeraMED logo

HeraMED(ASX) HMD

Market CapA$42.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-79%
5 Year-79%
1 Year+6%
1 Month+12%
A$0.04
+2.70%
+0.00Today
HeraMED last closing stock price
MetricPriceDate
Last closeAUD 0.042026-09-07
HeraMED stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.56%AUD 0.042026-08-31
1 month+11.76%AUD 0.032026-08-06
3 month-5%AUD 0.042026-06-09
Year to date+5.56%AUD 0.042025-12-31
1 year+5.56%AUD 0.042025-09-05
3 year-45.71%AUD 0.072023-09-07
5 year-79.46%AUD 0.192021-09-08
Since inception-78.99%AUD 0.182018-12-12

HeraMED Financials at a Glance

Market Cap

A$42.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$308.03K

Net Income (TTM)

-$5.25M

EPS (TTM)

-A$0.00

P/E Ratio

-11.94

Dividend

A$0.00

Beta (Volatility)

0.14 (Low)

Price

A$0.04

Volume

0

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.03 - A$0.06

Estimated Earnings Date

May 31, 2025

HMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About HeraMED

HeraMED Limited is a healthcare technology company focused on developing innovative at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. The company aims to enhance maternity care through its advanced digital solutions, catering to consumers in Australia, Europe, and Israel.

Products and Services
  • HeraBEAT: A device for expectant mothers to monitor their baby's heartbeat
  • HeraCARE: A digital platform for effective maternity care management
  • EchoBEAT: An upcoming evolution in pregnancy monitoring tools
Growth Outlook
  • Strategic partnership with Mayo Clinic enhances product development
  • Expansion into European markets is underway, increasing potential customer base
  • Focus on AI-driven solutions aims to improve pregnancy monitoring accuracy
Financial Highlights
  • Recent quarterly revenue of 102,691 reflects a growing market presence
  • Cash and cash equivalents reached 914,652, providing operational stability
  • Gross profit margin improved to 94.8% in the latest quarter
HeraMED Limited is positioned in the medical devices industry, focusing on innovative solutions for maternity care. The company's flagship products, HeraBEAT and HeraCARE, are designed to empower expectant mothers with the ability to monitor their pregnancies from home. The anticipated launch of EchoBEAT and the integration of AI technology through Orion are expected to further enhance the company's offerings. The growth outlook for HeraMED is promising, bolstered by a strategic partnership with Mayo Clinic, which is expected to drive advancements in the HeraCARE platform. Additionally, the company's efforts to expand into European markets could significantly increase its customer base, while the focus on AI-driven solutions aims to improve the accuracy of pregnancy monitoring. Financially, HeraMED has shown resilience, with a recent quarterly revenue of 102,691, indicating a growing market presence. The company also reported cash and cash equivalents of 914,652, which provides a buffer for ongoing operations. Notably, the gross profit margin has improved to 94.8% in the latest quarter, reflecting effective cost management and operational efficiency. Overall, HeraMED Limited presents an intriguing opportunity for investors interested in the healthcare technology sector, particularly in innovative solutions for maternity care.
AI Generated • Aug 22, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

17,000

CEO

Anoushka Gungadin, MBA

Website

www.hera-med.com

Headquarters

Hawthorn East, VIC 3123, AU

HMD Financials

Key Financial Metrics (TTM)

Gross Margin

92.92%

Operating Margin

-2162.24%

Net Income Margin

-2295.93%

Return on Equity

-198.77%

Return on Capital

-294.21%

Return on Assets

-109.42%

Earnings Yield

-8.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$42.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.16B

Volume

0

Avg. Volume

498.71K

Financials (TTM)

Gross Profit

$215.25K

Operating Income

-$5.12M

EBITDA

-$4.69M

Operating Cash Flow

-$4.76M

Capital Expenditure

$36.37K

Free Cash Flow

-$4.73M

Cash & ST Invst.

$2.03M

Total Debt

$0.00

HeraMED Performance Analysis

HeraMED annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 315,789173.5%
20232023-12-31USD 606,22692.0%
20242024-12-31USD 364,328-39.9%
20252025-12-31USD 293,380-19.5%
HeraMED sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-5.9%
Q22025-06-30-19.1%
Q42025-12-3111.9%
Q22026-06-30-100.0%
HeraMED annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.03-24.4%
20232023-12-31USD -0.03-21.1%
20242024-12-31USD -0.01-59.4%
20252025-12-31USD -0.00-62.1%
HeraMED sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3177.3%
Q22025-06-3015.0%
Q42025-12-3129.4%
Q22026-06-3016.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$1.94K

-103.1%

Gross Margin

0.00%

N/A

Market Cap

A$42.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$7.14M

N/A

Employees

6

N/A

Net Income

-$1.11M

+48.4%

EBITDA

-$1.11M

+46.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.03M

+116.3%

Total Debt

$0.00

-100.0%

Accounts Receivable

$61.04K

-70.9%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.09%

N/A

Return on Invested Capital

-1.16%

N/A

Free Cash Flow

-$1.03M

+43.9%

Operating Cash Flow

-$1.03M

+42.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EYE.AXNova Eye Medical Limited
A$0.14+0.00%
RHY.AXRhythm Biosciences Limited
A$0.09-2.30%
OSL.AXOncoSil Medical Ltd
A$0.91-12.92%
BDX.AXBCAL Diagnostics Limited
A$0.07-2.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About HMD

What is the current price of HeraMED?

HeraMED is trading at A$0.04 per share.

What is the 52-week range for HeraMED?

Over the past 52 weeks, HeraMED has traded between A$0.03 and A$0.06.

How much debt does HeraMED have?

As of the most recent reporting period, HeraMED reported total debt of $0.00.

How much cash does HeraMED have on hand?

HeraMED reported $1.37M in cash and cash equivalents in its most recent financial results.

What is HeraMED’s dividend yield?

HeraMED does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services